SAB Biotherapeutics Stock Forum

$SAB Biotherapeutics(SABS.US)$ Reuters· just
FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

$SAB Biotherapeutics(SABS.US)$
NEWS
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...

$SAB Biotherapeutics(SABS.US)$ SAB-142 In addition to the currently approved and ongoing Phase 1, there is plans to bring this program to IND and CTA filings with global regulatory authorities by the mid-2024. As there are unmet medical needs globally for disease-modifying treatments of T1D, they are going to work with global health authorities and file clinical trial applications and clinical trial notifications in other countries to have a global footprint and reach patients with T1D wor...

4/17/24 Watchlist 📊⚡️📊⚡️📊⚡️📊
$BYND Cannasoft(BCAN.US)$ $SAB Biotherapeutics(SABS.US)$ $Macatawa Bank(MCBC.US)$ $Dragonfly Energy(DFLI.US)$ $My Size(MYSZ.US)$ $SoundHound AI(SOUN.US)$ $ARK 21Shares Bitcoin ETF(ARKB.US)$  
📊⚡️📊 #stock_drift24
⭐️just a watchlist, not financisl advice⭐️

$SAB Biotherapeutics(SABS.US)$ SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far

$SAB Biotherapeutics(SABS.US)$
NEWS
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. (Nasdaq: SABS) provides an update on the SAB-142 trial, reporting completion of dosing the third cohort with no observation of serum sickness. The Phase 1 clinical trial aims to investigate safety, tolerability, pharmacokinetics, and immunogenicity of SAB-142, a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes (T1D).
MIAMI BEACH, Fla., April ...

$SAB Biotherapeutics(SABS.US)$ SAB Biotherapeutics: on April 12, Completed Dosing of Cohort 3 for Phase One Trials of SAB-142, Has Not Observed Any Instances of Serum Sicknesses

$Heron Therapeutics(HRTX.US)$ announced partnership today and broke resistance Thursday. FDA  approval in 15 days.It gaps at 1.95.  Will run as high as 5.50.
$Liquidia(LQDA.US)$ Also has FDA approval in 15 days. Has no resistance. Will make a 5 year high after it breaks 22.00.
$Trio Petroleum(TPET.US)$  Announced news on Thursday. The last time it released similar news it took it a couple of days before it got going. After .40 it will run to .62 for 100% profit.
$Sharps Technology(STSS.US)$  Ran up i...